Previous 10 | Next 10 |
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S. Food and Drug A...
Going into the second month of this new year, biotech investors have a lot to look forward to. In particular, there are many promising drug candidates awaiting approval from the Food and Drug Administration (FDA), as well as a number of well-established drugs that are on the cusp of receiving ex...
Shares of Amarin (NASDAQ: AMRN) , a mid-cap drugmaker, dropped by 13.4% last month, according to data from S&P Global Market Intelligence . Shares took a beating in January for two reasons: First, Amarin has long been rumored to be a top buyout candidate. A worthwhile tender o...
Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...
Amarin (NASDAQ: AMRN) stock climbed 58% last year, and that could be just the beginning. A new indication for its already-marketed drug could be a game changer for the company and its investors. The average analyst price target predicts an upside of 50% from its current price. That and...
HLS Therapeutics ( OTCPK:HLTRF ) announces that Vascepa (icosapent ethyl) will be available in Canada on or about February 18. More news on: HLS Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Read more ...
Intercept Pharmaceuticals (NASDAQ: ICPT) is in the enviable position of many biotech companies. It boasts a marketed drug on pace to deliver more than $200 million in sales for 2019 and is anticipating an upcoming decision from the Food and Drug Administration that could grant it the fi...
Generally speaking, biotech stocks were one of the best places to put your money in 2019. The iShares Nasdaq Biotechnology ETF gained a stellar 25.2% last year, despite the political wrangling over prescription drug prices in the United States. Fortunately, this upward trend should continue un...
Amarin (NASDAQ: AMRN) is about to make a boatload of money. Probably no one familiar with the biotech would argue that point. In December, the FDA gave the go-ahead to a new label expansion for Amarin's sole approved drug, Vascepa, in reducing cardiovascular risk. While Vascepa has been o...
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...